Charles River Laboratories International, Inc. has reported its third-quarter results for 2026, highlighting a significant recovery in its financial performance. The company announced revenue of $982.7 million, with a GAAP earnings per share of $6.86 and a non-GAAP earnings per share of $3.09. This performance marks a noteworthy return to organic revenue growth, which increased by 4.7% compared to previous quarters. The results indicate a positive trajectory for the company and the broader commercial physical and biological research industry.

Founded in Wilmington, Massachusetts, Charles River Laboratories specializes in services related to commercial physical and biological research, classified under SIC code 8731. The company trades on the New York Stock Exchange under the ticker symbol CRL. Charles River has consistently been recognized for its contributions to the life sciences sector, providing essential services to pharmaceutical and biotechnology companies.

The SEC filing dated November 4, 2026, reveals that the company’s operating margin has also improved, with a non-GAAP operating margin rising by 330 basis points to 23.0% and a GAAP operating margin increasing by 730 basis points to 20.6%. This improvement is attributed to a combination of factors, including a reversal of tax reserves and enhanced operational efficiencies. Charles River’s net income for the quarter reached $333.1 million, a substantial increase from $54.4 million in the same period last year.

In the filing, Charles River highlighted several key achievements during the quarter. The company has increased its guidance for the remainder of 2026, forecasting higher revenue and non-GAAP earnings per share than previously expected. The guidance revision reflects a strong performance in the Discovery and Safety Assessment (DSA) segment and a favorable tax rate. The company’s strategic initiatives, including its 'Pathway to Purpose' vision, aim to enhance operational excellence and scientific leadership.

Looking ahead, Charles River Laboratories is expected to continue its focus on modernization and innovation within its operations. The company has made strides in advancing its Endosafe Cartridge Technology and has partnered with Autolomous to enhance its Apollo platform, which aims to digitize laboratory workflows. These advancements are likely to position the company favorably against its competitors in the commercial research sector.

The filing does not specify what will happen next, but the raised guidance and strong quarterly results suggest that Charles River Laboratories is poised for continued growth and success in the coming quarters.